Also, BRAF inhibitors result in the development of secondary keratoacanthomas and cutaneous squamous cell carcinomas, originating from a paradoxical activation of the MAPK pathway in tumor cells [96, 97, 98]. The gene discussed is BRAF; the disease is neoplasm.